
    
      This is a descriptive, cross-sectional, non-interventional study of participants with gout.
      The study will evaluate the impact of the 2019 labeling changes (boxed warning and modified
      indication), based upon results of the cardiovascular safety of febuxostat and allopurinol in
      participants with gout and cardiovascular morbidities (CARES) trial, on febuxostat
      utilization.

      The study will evaluate data from approximately 24046 participants. The data will be
      collected from optum clinformatics dataMart (CDM) including the medicare advantage
      administrative US claims database and the IQVIA pharmetrics plus claims database.

      All participants will be enrolled in a single observational cohort. This trial will be
      conducted in the United States. The overall duration of this study is approximately 14
      months.
    
  